PUBLIC COMPANY
save$ARWRARROWHEAD PHARMACEUTICALS, INC.
$ARWR59.90-0.98%Pasadena, CA, USupdated 17d ago
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference (RNAi) mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
community read0 votes
pipeline
4
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 21Phase 31Marketed1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
- phase3Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
- phase2Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
- phase1A First-In-Human Study of ARO-033 in Adult Participants
- phase3A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
- phase2A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
- phase2Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
- phase2Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
🐶 Hiring Signal
News
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 3d ago
- Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data dropArrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier…biospace · 1mo ago
- Roche expands obesity R&D footprint with Rona deal worth $1B+Roche has gained access to a genetic obesity approach from China's Rona Therapeutics for up to $100 million in upfront and near-term payments.biospace · 1mo ago
- Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity raceRoche has committed $100 million in upfront and near-term payments to license Rona Therapeutics’ ALK7 drug candidate, joining Alnylam, Arrowhead, GSK and Novo Nordisk in an emerging obesity niche.fiercebiotech · 1mo ago
- Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts splitSafety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.biospace · 2mo ago
- Epicrispr lands $90M to advance epigenetic editing drug for rare muscle diseaseThe startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.biopharma_dive · 3mo ago
- ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culpritEarly indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.biopharma_dive · 3mo ago
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 3mo ago
- Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drugWith Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…biospace · 3mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that